Tevogen Bio (NASDAQ:TVGN) Downgraded by D. Boral Capital to “Hold”

D. Boral Capital downgraded shares of Tevogen Bio (NASDAQ:TVGN) from a buy rating to a hold rating in a research note released on Wednesday morning, MarketBeat reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tevogen Bio in a research report on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $2.00.

Tevogen Bio Price Performance

TVGN opened at $0.19 on Wednesday. Tevogen Bio has a 12-month low of $0.17 and a 12-month high of $1.51. The firm’s fifty day moving average price is $0.31 and its 200 day moving average price is $0.53. The stock has a market capitalization of $37.00 million, a PE ratio of -0.98 and a beta of -0.76.

Shares of Tevogen Bio are going to reverse split before the market opens on Friday, March 6th. The 1-50 reverse split was announced on Wednesday, March 4th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, March 5th.

Institutional Trading of Tevogen Bio

Several large investors have recently added to or reduced their stakes in TVGN. Goldman Sachs Group Inc. raised its position in shares of Tevogen Bio by 126.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after purchasing an additional 152,572 shares during the period. Deutsche Bank AG grew its stake in Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after buying an additional 130,738 shares during the last quarter. Finally, Bridgeway Capital Management LLC raised its holdings in Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after acquiring an additional 33,000 shares during the period.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.